INOVIO Pharmaceuticals
NEWS ALERT

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Press Releases

INOVIO to Participate in Upcoming Investor Conferences in May

Posted on April 29, 2024

INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024

Posted on April 29, 2024

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Posted on April 15, 2024

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

Posted on March 26, 2024

INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Posted on March 6, 2024

INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024

Posted on February 21, 2024

INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Posted on February 7, 2024

INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split

Posted on January 31, 2024

INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader

Posted on January 22, 2024

INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi)

Posted on January 4, 2024

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2026 INOVIO Pharmaceuticals. All rights reserved.